A few years ago, biotech company (NASDAQ: NVAX) looked like a promising stock. It emerged as a leader in the development of a COVID-19 vaccine, which sent its share price through the roof.

However, there have been a lot of negative developments for Novavax since then, and as a result, the biotech has given up all of its gains. Is there any hope for Novavax? If the company can improve its situation, investors who get in on the stock now could earn outsized returns.

Let's find out whether Novavax is likely to pull off a comeback or whether the best the company has to offer is in the rear-view mirror.

Continue reading

Source Fool.com